{
    "clinical_study": {
        "@rank": "115999", 
        "arm_group": [
            {
                "arm_group_label": "TAU + ABMT active", 
                "arm_group_type": "Experimental", 
                "description": "Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor\nAttention Bias Modification Treatment (ABMT) - active"
            }, 
            {
                "arm_group_label": "TAU + AMBT placebo", 
                "arm_group_type": "Sham Comparator", 
                "description": "Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor\nAttention Bias Modification Treatment (ABMT) - placebo (sham)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this project is to test the combination of active or placebo Attentional\n      Bias Modification Treatment (ABMT) to usual treatment for anxiety disorder patients\n      resistant to antidepressants."
        }, 
        "brief_title": "Attention Retraining for Anxiety Disorder Patients Resistent to Antidepressants", 
        "condition": [
            "Generalized Anxiety Disorder", 
            "Social Anxiety Disorder", 
            "Panic Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anxiety Disorders", 
                "Panic Disorder", 
                "Phobic Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary diagnosis of Generalized Anxiety Disorder, Panic Disorder or Social Anxiety\n             Disorder according to the International Neuropsychiatric Interview psychiatric\n             interview (M.I.N.I.)\n\n          -  Current treatment for the anxiety disorder with antidepressants with an  appropriate\n             dose for at least 3 months;\n\n          -  Score on OASIS (Overall Anxiety Severity and Impairment Scale)equal or greater than 8\n\n        Exclusion Criteria:\n\n          -  Other psychiatric disorder that causes more impairment and suffering than generalized\n             anxiety disorder, panic disorder or social anxiety disorder in the clinical\n             evaluation\n\n          -  Current Cognitive Behavior Therapy\n\n          -  Marked intellectual disability (clinically evident)\n\n          -  Suicidal ideation or suicide plan at the time of assessment(M.I.N.I.)\n\n          -  Psychotic disorder (M.I.N.I.)\n\n          -  Bipolar disorder type I (M.I.N.I.)\n\n          -  Abuse / Dependence substances (M.I.N.I.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01906268", 
            "org_study_id": "15224913.3.0000.5327"
        }, 
        "intervention": [
            {
                "arm_group_label": "TAU + ABMT active", 
                "description": "The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.\nNumber of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)", 
                "intervention_name": "Attentional Bias Modification Treatment (ABMT) - Active", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "TAU + AMBT placebo", 
                "description": "The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.\nNumber of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)", 
                "intervention_name": "Attentional Bias Modification Treatment - Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antidepressive Agents", 
                "Serotonin Uptake Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Generalized Anxiety Disorder", 
            "Social Anxiety Disorder", 
            "Panic Disorder", 
            "Antidepressants Resistant", 
            "Attentional Bias Modification Treatment (ABMT)", 
            "Attentional Retraining", 
            "Adjuvant Therapy"
        ], 
        "lastchanged_date": "July 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90040-371"
                    }, 
                    "name": "Hospital de Cl\u00ednicas de Porto Alegre"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90040-371"
                    }, 
                    "name": "Hospital de Cl\u00ednicas de Porto Alegre"
                }, 
                "investigator": [
                    {
                        "last_name": "Rachel Montagner, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Giovanni A Salum Junior", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Juliana L Muller", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Clarissa Trentini", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Attentional Bias Modification Treatment (ABMT) as Adjuvant Therapy for Anxiety Disorder Patients Resistent to Antidepressants: A Randomized Clinical Trial", 
        "other_outcome": {
            "description": "Change in bias in attention orienting and executive function measures from baseline to endpoint and 3-months follow-up", 
            "measure": "Dot-probe and Executive Function Measures", 
            "safety_issue": "No", 
            "time_frame": "Endpoint and 3-months follow-up"
        }, 
        "overall_contact": {
            "email": "rachelmontagner@hotmail.com", 
            "last_name": "Rachel Montagner, MD", 
            "phone": "+55 51 3359 8983"
        }, 
        "overall_official": {
            "affiliation": "Hospital de Cl\u00ednicas de Porto Alegre", 
            "last_name": "Gisele G Manfro, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Disorder non-specific primary outcome:\nScore change on OASIS (Overall Anxiety Severity and Impairment Scale) from baseline to endpoint and 3-months follow-up", 
                "measure": "Overall Anxiety Severity and Impairment Scale (OASIS)", 
                "safety_issue": "No", 
                "time_frame": "Endpoint and 3-months follow-up"
            }, 
            {
                "description": "Disorder-specific primary outcome:\nFor patients with Panic Disorder - change from baseline to endpoint and 3 months follow-up in the PDSS\nFor patients with Generalized Anxiety Disorder - change from baseline to endpoint and 3 months follow-up in the GAD-7\nFor patients with Social Anxiety Disorder - change from baseline to endpoint and 3 months follow-up in the LSAS", 
                "measure": "Panic Disorder Severity Scale (PDSS), Generalized Anxiety Disorder 7-item Scale (GAD-7) or Liebowitz Social Anxiety Scale (LSAS)", 
                "safety_issue": "No", 
                "time_frame": "Endpoint and 3-months follow up"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01906268"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Score change on BDI from baseline to endpoint and 3-months follow up", 
                "measure": "Beck Depression Inventory (BDI)", 
                "safety_issue": "No", 
                "time_frame": "Endpoint and 3-months follow-up"
            }, 
            {
                "description": "Score change on BAI from baseline to endpoint and 3-months follow up", 
                "measure": "Beck Anxiety Inventory (BAI)", 
                "safety_issue": "No", 
                "time_frame": "Endpoint and 3-months follow-up"
            }, 
            {
                "description": "Score change on Cross-D from baseline to endpoint and 3-months follow up", 
                "measure": "DSM-5 Cross-Disorder Dimensional Scale [Brazilian version]", 
                "safety_issue": "No", 
                "time_frame": "Endpoint and 3-months follow-up"
            }, 
            {
                "description": "Score Change on POMS from baseline to endpoint and 3-months follow up.", 
                "measure": "Profile of Mood States (POMS)", 
                "safety_issue": "No", 
                "time_frame": "Endpoint and 3-months follow-up"
            }, 
            {
                "description": "Dichotomous outcome: percentage of patients with a score of 2 or less at the endpoint and 3-months follow-up evaluations", 
                "measure": "Clinical Global Impression(CGI)", 
                "safety_issue": "No", 
                "time_frame": "Endpoint and 3-months follow-up"
            }
        ], 
        "source": "Hospital de Clinicas de Porto Alegre", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital de Clinicas de Porto Alegre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}